Senti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc. is a U.S.-based biotechnology company developing engineered cell and gene therapies built around synthetic biology and gene-circuit design. Its work centers on preclinical and clinical-stage product candidates, with development activities, manufacturing coordination, and collaboration arrangements conducted through its corporate and subsidiary structure.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueEngineered therapeutic candidates designed to target disease through modified cells.
Synthetic biology platforms used to design programmable therapeutic behavior.
Fees and milestone-like payments from research or option agreements with partners.
Discovery and early-stage development work supporting future product candidates.
Development and scale-up activities needed to produce clinical-grade material.
Customers
Senti’s direct customers are primarily collaboration partners, research counterparties, and future commercial buyers of approved therapies rather than end-market patients today. The company’s current economic model depends on licensing, option agreements, and development partnerships while its product candidates move through clinical testing and manufacturing scale-up.
Partners license, option, or co-develop Senti's synthetic biology and cell therapy programs.
Organizations that pay for access to programs, data, or development rights during early-stage work.
Hospitals, investigators, and trial operators that support testing of product candidates.
Oncology treatment centers and hospitals that would use approved therapies if launched.
Strategy
Senti’s strategy is to concentrate resources on a small number of lead programs while using partnerships to extend the reach of its platform technology. The company also relies on external manufacturing and collaboration structures to advance clinical development without building a full commercial infrastructure before approval.
The lead program is central to validating the platform and creating future value.
Partnerships can fund development and broaden the platform without full internal spend.
A lean structure reduces the need to build commercial and manufacturing infrastructure too early.
Geography
Senti is headquartered in the United States and conducts its core research, development, and corporate activities there. The company also references international collaboration and partnership exposure, including a stated focus on partnership activity in China for one program, which adds regulatory and execution complexity outside the U.S.
Risks
Senti is an early-stage biotechnology company with no approved products, so its value depends on successful clinical development, regulatory outcomes, and access to funding. The business also depends on third-party manufacturing and collaboration arrangements, which can create concentration, execution, and collectibility risk if partners underperform.
- Clinical development failureImpact: CriticalLikelihood: High
Product candidates may not show sufficient safety or efficacy in trials.
Exposure: Lead programs such as SENTI-202
- Financing and dilution riskImpact: HighLikelihood: High
The company has no product sales and relies on external capital to fund operations.
Exposure: Equity and convertible note financing
- Manufacturing partner dependenceImpact: HighLikelihood: High
Clinical supply is reliant on GeneFab and other third parties for scale-up and continuity.
Exposure: SENTI-202 manufacturing
- Collectibility and counterparty riskImpact: MediumLikelihood: High
Related-party sublease and collaboration income depend on partner payments.
Exposure: GeneFab sublease and BlueRock agreement
- International collaboration riskImpact: MediumLikelihood: Medium
Cross-border partnerships can face regulatory, political, and operational friction.
Exposure
Accounting
Judgemental itemsRevenue from option exercise period extensions is recognized ratably over the period, affecting timing.
Impact: BlueRock-related collaboration revenue
Sublease income can be reversed if collectibility is no longer probable under lease accounting rules.
Impact: GeneFab and headquarters sublease income
Convertible notes, options, and economic share arrangements may require remeasurement.
Impact: Reported other income/expense and balance sheet liabilities
Lease changes can create one-time gains or losses that distort period comparability.
Impact: Operating results and lease-related line items
External services and supplies drive most development spend and can shift sharply quarter to quarter.
Impact: Comparability of research and development expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Solid Biosciences Inc.
SLDB · Biological Products, (No Diagnostic Substances)
Calidi Biotherapeutics, Inc.
CLDI · Biological Products, (No Diagnostic Substances)
Sana Biotechnology, Inc.
SANA · Biological Products, (No Diagnostic Substances)
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Lunai Bioworks Inc.
LNAI · Pharmaceutical Preparations
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Last updated: 24/09/2026